Archives: MeetingInsights

2022 ASCO® Annual Meeting: Updates on the Treatment of Advanced Renal Cell Carcinoma

At the 2022 American Society of Clinical Oncology® (ASCO®) Annual Meeting, several studies were presented on recent advances in the treatment of advanced renal cell carcinoma. David Braun, MD, PhD, shares some key takeaways from the meeting and highlights cutting-edge research reported at the conference and in the recent medical literature that could advance care for patients with aRCC

Treatment Advances in Metastatic Breast Cancer: Highlights from ASCO® 2022

The 2022 American Society of Clinical Oncology (ASCO®) Annual Meeting introduced updated data on newer therapeutic options for metastatic breast cancer. Adam M Brufsky, MD, PhD, FACP, discusses the implications of socioeconomic status on breast cancer care, key findings of standout studies presented at the conference, and the potential role of biomarker analyses in the management of patients with advanced breast cancer.

Treatment Approaches for Renal Cell Carcinoma: Insight From the 2022 Genitourinary Cancers Symposium

This Q&A was edited for clarity and length. Disclosure Robert Dreicer, MD, has reported affiliations with Astellas Pharma, Inc; AstraZeneca PLC; AVEO Pharmaceuticals, Inc; Bayer AG; Bristol-Myers Squibb; EMD Serono, Inc; Exelixis, Inc; Hinova Pharmaceuticals, Inc; Infinity Pharmaceuticals, Inc; Janssen Oncology Inc; Merck & Co., Inc; Myovant Sciences; Novartis International AG; Pfizer, Inc; Propella Therapeutics…

Treatment Approaches for Advanced Hepatocellular Carcinoma: Insight From the 2022 Gastrointestinal Cancers Symposium

This Q&A was edited for clarity and length. Disclosure Muhammad Shaalan Beg, MD, has reported affiliations with Array BioPharma, Inc; AstraZeneca PLC; Cancer Commons, Foundation Medicine, Inc; Ipsen; Legend Biotech; Agios Pharmaceuticals, Inc; ArQule, Inc; Bristol-Myers Squibb; CASI Pharmaceuticals, Inc; Celgene; Five Prime Therapeutics, Inc; Genentech, Inc; ImmuneSensor Therapeutics; EMD Serono; SillaJen, Inc; and Tolero…

Practice-Changing Presentations in Renal Cell Carcinoma: Insights From ASCO® 2021

Disclosure Elizabeth Plimack, MD, reported affiliations with Bristol-Myers Squibb, Genentech/Roche, Janssen, Merck Sharp & Dohme, Flatiron, Seattle Genetics, Pfizer, AstraZeneca, Infinity Pharmaceuticals, MEI Pharma, Pfizer, and Astellas Pharma. References Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: randomized, double-blind, phase III Keynote-564…